Further studies would be beneficial to ascertain the role of bronchoscopy in the investigative pathway of lung cancer in patients with normal CT scan.

**Abstract P166 Table 1** Cross-Tabulation of CT and bronchoscopy results

<table>
<thead>
<tr>
<th></th>
<th>Normal CT scan</th>
<th>Non diagnostic CT scan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bronchoscopy results</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neoplasia</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Benign</td>
<td>12</td>
<td>10</td>
</tr>
</tbody>
</table>

**P167 PATHOLOGICAL CONFIRMATION RATE OF LUNG CANCER IN ENGLAND USING THE NLCA DATABASE**

doi:10.1136/thoraxjnl-2012-202678.228

1AKhakwani, 2ALRich, 3JTLata, 4HPowell, 5RASTanley, 6DBaldwin, 7RHubbard. 1Division of Epidemiology and Public Health, University of Nottingham, Nottingham, United Kingdom; 2Department of Respiratory Medicine, Nottingham University Hospital, Nottingham, United Kingdom; 3Nottingham Respiratory Research Unit, University of Nottingham, Nottingham, United Kingdom; 4Clinical Audit Support Unit, Health and Social Care Information Centre, Leeds, United Kingdom

**Introduction**

The majority of people with lung cancer should have pathological confirmation of their diagnosis. The National Lung Cancer Audit (NLCA) recommends that NHS trusts obtain pathology (histology or cytology) for 75% of their lung cancer patients, however this figure was arbitrarily chosen and the optimal pathological confirmation rate is unknown.

**The Aims** of this study were to provide a simple means of benchmarking appropriate pathological confirmation rates by stratifying patients into groups, and whether obtaining pathology based on those groups is associated with a survival benefit.

**Methods**

Using the NLCA database, we calculated the proportion of patients with non-small cell and small cell lung cancer, first seen between 1st January 2004 and 31st December 2010, who had pathological confirmation of their diagnosis. Using bivariate analysis, we identified the features which were most strongly associated with having pathology. We stratified our cohort according to these features and developed 4 groups (Table 1) based on the percentage of pathology obtained by the majority of NHS trusts during the study period.

**Results**

We analysed data on 136,993 individuals. The median age at diagnosis was 72 years (IQR 64–79 years). Performance status (PS) and age were the features most strongly associated with having a pathological diagnosis. Pathological confirmation was associated with a survival benefit at 6 months for patients in groups 1–3 and at 1 year for patients in group 1 & 2 having adjusted for confounders (HR 0.95 & 0.89 respectively). This survival benefit was removed when adjusted for treatment with chemotherapy (Table 2).

**Discussion**

Stratifying by age and PS, is a simple means of benchmarking pathological confirmation rates which is more appropriate than current recommendations. We have shown better survival at six months and one year for patients who had pathological confirmation of lung cancer in groups 1 and 2 (younger patients with better PS), even after adjusting for confounders. Much of this survival advantage was accounted for by adjusting for the use of chemotherapy. We would suggest, therefore, that clinicians should aim to achieve a pathologically confirmed diagnosis in every patient in groups 1 & 2.

**Abstract P167 Table 1** Sub groups of patients stratified by age and performance status

<table>
<thead>
<tr>
<th>Group</th>
<th>Age &amp; PS</th>
<th>Pathology confirmed (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1</td>
<td>PS 0/1 &amp; age &lt;65</td>
<td>83.9</td>
</tr>
<tr>
<td>Group 2</td>
<td>PS 0/1 &amp; age &gt;65</td>
<td>73.9</td>
</tr>
</tbody>
</table>

**P168 FACTORS ASSOCIATED WITH ADVANCED STAGE LUNG CANCER AT DIAGNOSIS – A RETROSPECTIVE COHORT STUDY**

doi:10.1136/thoraxjnl-2012-202678.229

E Ghorani, B O’Leary, K Asif, S Hafiz, AK Reinhardt. Whips Cross Hospital, London, UK

**Introduction**

Lung cancer is a major cause of mortality in the UK, with survival related to stage of disease at presentation. Better understanding of factors contributing to presentation delay might aid earlier identification and assessment of patients. Here we set out to characterise demographic features of the late presenting population at an East London hospital.

**Methods**

Local lung cancer diagnoses between June 2005 and November 2011 (n=554) were retrospectively determined from the National Lung Cancer Audit database. Cases for whom staging information at diagnosis was available, were selected for study (n=460) disease. Socioeconomic quintiles based on patients’ postcodes were defined using the Income domain of the Index of Multiple Deprivation 2010. Data were analysed by logistic regression in SPSS.

**Results**

We found increasing age (ORs 0.95, 0.55, 0.58 for age groups <60, 60–69, 70–79 and ≥80 years respectively, p=0.027) to be associated with decreased risk of late presentation. Male gender (OR=1.59, 95% CI 1.06–2.38, p=0.016) and emergency presentation as opposed to community based referral to services (OR=1.92, 95% CI 1.19–3.10, p=0.008) were associated with advanced stage disease at diagnosis.

Socioeconomic group was not found to contribute significantly to stage of disease at presentation.

**Conclusion**

We report that age, gender but not socioeconomic status are risk factors for late stage of lung cancer at diagnosis. These findings are in line with a recent large study of the East of England cancer registry (BJC 2012; 106:1068–1075). We extend that work to show a relationship between mode of presentation and disease stage at diagnosis, in keeping with national data indicating that emergency presentation is associated with poorer survival outcomes (NCIN 2010).

In summary, this study adds to the increasing evidence that patient factors are associated with potentially avoidable late stage presentations of lung cancer, reiterating the need for targeted health promotion activities to engage at risk patient groups.